Overview of endocrinopathies associated with β-thalassaemia major

Internal Medicine Journal

Volumn 40, Issue 10, 2010, Pages 689-696

  Perera, N J ^a   Lau, N S ^a   Mathews, S ^b   Waite, C ^b   Ho, P J ^b   Caterson, I D ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Endocrinopathy; Monitoring and treatment guideline; Thalassaemia major

Indexed keywords

CALCIFEDIOL; CALCIUM; DEFERASIROX; DEFEROXAMINE MESYLATE; ESTROGEN; FERRITIN; FOLLITROPIN; LUTEINIZING HORMONE; METFORMIN; PARATHYROID HORMONE; SOMATOMEDIN C; TESTOSTERONE; THYROID HORMONE; VITAMIN D; ZOLEDRONIC ACID;

ADULT; BETA THALASSEMIA; BLOOD TRANSFUSION; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; DISEASE ASSOCIATION; ENDOCRINE DISEASE; FEMALE; GROWTH DISORDER; HUMAN; HYPOGONADISM; HYPOTHYROIDISM; IMPAIRED GLUCOSE TOLERANCE; INFERTILITY; INSULIN DEPENDENT DIABETES MELLITUS; IRON CHELATION; IRON OVERLOAD; MALE; MORBIDITY; OSTEOPENIA; OSTEOPOROSIS; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; REVIEW; TESTOSTERONE BLOOD LEVEL; THALASSEMIA MAJOR;

ADULT; BETA-THALASSEMIA; COHORT STUDIES; COMORBIDITY; ENDOCRINE SYSTEM DISEASES; FEMALE; HUMANS; MALE; PRACTICE GUIDELINES AS TOPIC; RETROSPECTIVE STUDIES;

EID: 78650616521     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2010.02254.x     Document Type: Review

References (20)

1. Rund D, Rachmilewitz E. Medical progress, β-Thalassemia. N Engl J Med 2005; 353: 1135-46.
2. Olivieri NF. Medical Progress, the P-Thalassaemia. N Engl J Med 1999; 341: 99-109.
3. Fung EB, Harmatz PR, Lee PDK, Milet M, Bellevue R, Jeng MR et al.; The Multi-Centre Study of Iron Overload Research Group. Increased prevalence of iron-overload associated endocrinopathy in thalassemia versus sickle cell disease. Br J Haematol 2006; 135. 574-82.
4. Italian Working Group on Endocrine Complications in Non-endocrine Diseases. Multicentre study on prevalence of endocrine complications in thalassemia major. Clin Endocrinol 1995; 42: 581-6.
5. Ferrara M, Matarese SMR, Francese M, Borrelli B, Coppola A, Coppola L et al. Effect of VDR polymorphism on growth and bone mineral density in homozygous beta Thalassaemia. Br J Haematol 2001; 117: 436-40.
6. Jensen CE, Tuck SM, Agnes JE, Koneke S, Morris RW, Yardumian A et al. High prevalence of low bone mass in Thalassaemia major. Br J Haematol 1998; 103: 911-15.
7. Voskaridou E, Terpos E. New insights into the pathophysiology and management of osteoporosis in patients with beta thalassemia. Br J Haematol 2004; 127: 127-39.
8. Walton C, Kelly WF, Laing I, Bu'lock DE. Endocrine abnormalities in idiopathic haemochromatosis. Q J Med 1983; 52: 99-110.
9. Grundy RG, Woods KA, Savage MO, Evans JPM. Relationship of endocrinopathy to iron chelation status in young patients with Thalassaemia major. Arch Dis Child 1994; 71: 128-32.
10. Scacchi M, Danesi L, De Martin M, Dubini A, Foml A, Masalat D et al. Treatment with biosynthetic growth hormone of short thalassaemic patients with impaired growth hormone secretion. Clin Endocrinol 1991; 35: 335-9.
11. Skordis N, Michaelidou M, Savva SC, Ioannou Y, Rousounides A, Kleanthous M et al. The impact of genotype on endocrine complications in Thalassaemia major. Eur J Haematol 2006; 77: 150-6.
12. Telfer PT, Prestcott E, Holden S, Walker M, Hoffbrand AV, Wonke B. Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in Thalassaemia major. Br J Haematol 2000; 110: 971-7.
13. Farmaki K, Angelopoulos N, Anagnostopoulos G, Gotsis E, Rombopoulos G, Tolis G. Effect of enhanced iron chelation therapy on glucose metabolism in patients with beta-thalassemia major. Br J Haematol 2006; 134: 438-44.
14. Sheiner E, Levy A, Yerushalmi R, Katz M. Beta-thalassaemia minor during pregnancy. Obstet Gynecol 2004; 103: 1273-7.
15. Bielinski BK, Darbyshire PJ, Matheres L, Crabtree NJ, Kirk JMW, Stirling HF et al. Impact of disordered puberty on bone density in beta-thalassaemia major. Br J Haematol 2002; 120: 353-8.
16. Pollak RD, Rachmilewitz E, Blumenfeld A, Idelson M, Goldfarb AW. Bone mineral metabolism in adults with 3-Thalassaemia major and intermedia. Br J Haematol 2000; 111: 902-7.
17. Voskaridou E, Kyrtsonis MC, Terpos E, Skordili M, Theodoropoulos I, Bergele A et al. Bone resorption is increased in young adults with thalassaemia major. Br J Haematol 2001; 112: 36-41.
18. Perrotta S, Cappelini MD, Bertolodo F, Servedio V, Iolascon A. Osteoporosis in β-thalassaemia major patients: analysis of the genetic background. Br J Haematol 2000; 111:461-6.
19. Singer ST, Vichinsky EP. Bone disease in (β-Thalassaemia. Lancet 1999; 354: 881-2.
20. Voskaridou E, Terpos E, Spina G, Palermos J, Rahemtulla A, Loutradi A etal. Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassemia. Br J Haematol 2003; 123: 730-7.